Gefitinib‑induced interstitial pneumonia: A case report and review of the literature

Luo,Changqin; Lv,Meiling; Li,Yuyao; Liu,Peijun; Yang,Jin

doi:10.3892/etm.2014.1495

Gefitinib‑induced interstitial pneumonia: A case report and review of the literature

Authors:
- Changqin Luo
- Meiling Lv
- Yuyao Li
- Peijun Liu
- Jin Yang
View Affiliations

Affiliations: Department of Clinical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University College of Medicine, Xi'an, Shaanxi 710061, P.R. China, Center for Translational Medicine, The First Affiliated Hospital of Xi'an Jiaotong University College of Medicine, Xi'an, Shaanxi 710061, P.R. China
Published online on: January 21, 2014 https://doi.org/10.3892/etm.2014.1495
Pages: 855-859

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to explore the clinical characteristics of and treatment strategies for interstitial pneumonia induced by gefitinib in patients with advanced non‑small cell lung cancer (NSCLC). The detailed clinical data of one patient with NSCLC and gefitinib‑induced interstitial pneumonia were compiled and a review of relevant previous studies was performed. Based on this case report and the review, the clinical characteristics, mechanisms and treatment strategies of this rare disease were analyzed. The analyses showed that older, male patients with a long smoking history, high smoking index and adenocarcinoma (particularly bronchoalveolar carcinoma) were more likely to suffer from interstitial pneumonia while taking gefitinib. The onset time of interstitial pneumonia was 1‑2 months subsequent to gefitinib administration. The clinical manifestations included chest tightness, shortness of breath, progressive dyspnea, severe hypoxemia and respiratory failure. Diffuse infiltration and alveolar interstitial shadows were observed on the chest tomography scan. In such circumstances, a timely judgment is required, in addition to the withdrawal of gefitinib treatment and the administration of high‑dose glucocorticoids, as well as oxygen inhalation and anti‑infective therapies, in order to relieve the symptoms. In conclusion, following the onset of gefitinib‑induced interstitial pneumonia, the discontinuation of gefitinib is likely to alleviate the suffering of the majority of patients. Early interstitial pneumonia is not an absolute index for the permanent discontinuation of gefitinib treatment. It is necessary to comprehensively consider the benefits and hazards of gefitinib for the patients.

View Figures

View References

1	Von Pawel J: Gefitinib (Iressa, ZD 1839): a novel targeted approach for the treatment of solid tumors. Bull Cancer. 91:E70–E76. 2004.PubMed/NCBI
2	Cerosimo RJ: Gefitinib: an adverse effects profile. Expert Opin Drug Saf. 5:469–479. 2006. View Article : Google Scholar : PubMed/NCBI
3	Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 21:2237–2246. 2003. View Article : Google Scholar : PubMed/NCBI
4	Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol. 22:777–784. 2004. View Article : Google Scholar : PubMed/NCBI
5	Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol. 22:785–794. 2004. View Article : Google Scholar : PubMed/NCBI
6	Ohyanagi F, Ando Y, Nagashima F, et al: Acute gefitinib-induced pneumonitis. Int J Clin Oncol. 9:406–409. 2004. View Article : Google Scholar : PubMed/NCBI
7	Teramoto S, Yamamoto H and Ouchi Y: Clinical efficacy and toxicity of gefitinib in patients with lung cancer. Lancet. 361:1992–1993. 2003. View Article : Google Scholar : PubMed/NCBI
8	Sumpter K, Harper-Wynne C, O’Brien M and Congleton J: Severe acute interstitial pneumonia and gefitinib. Lung Cancer. 43:367–368. 2004. View Article : Google Scholar
9	Umemura S, Kishino D, Tabata M, et al: Systemic tumor embolism mimicking gefitinib (‘IRESSA’)-induced interstitial lung disease in a patient with lung cancer. Intern Med. 44:979–982. 2005.PubMed/NCBI
10	Suzuki M, Asahina H, Konishi J, et al: Recurrent gefitinib-induced interstitial lung disease. Intern Med. 47:533–536. 2008. View Article : Google Scholar : PubMed/NCBI
11	Aoe K, Hiraki A, Murakami T, et al: Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy. Anticancer Res. 25:415–418. 2005.PubMed/NCBI
12	Nagaria NC, Cogswell J, Choe JK and Kasimis B: Side effects and good effects from new chemotherapeutic agents. Case 1 Gefitinib-induced interstitial fibrosis. J Clin Oncol. 23:2423–2424. 2005. View Article : Google Scholar : PubMed/NCBI
13	Tian Q and Chen LA: Erlotinib achieved partial response in a non-small cell lung cancer patient with gefitinib-induced interstitial lung disease. Case Rep Oncol. 4:464–466. 2011. View Article : Google Scholar : PubMed/NCBI
14	Kuo LC, Lin PC, Wang KF, et al: Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review. Med Oncol. 28:79–82. 2011. View Article : Google Scholar : PubMed/NCBI
15	Seto T, Seki N, Uematsu K, et al: Gefitinib-induced lung injury successfully treated with high-dose corticosteroids. Respirology. 11:113–116. 2006. View Article : Google Scholar : PubMed/NCBI
16	Ohyanagi F, Ando Y, Nagashima F, Narabayashi M and Sasaki Y: Acute gefitinib-induced pneumonitis. Int J Clin Oncol. 9:406–409. 2004. View Article : Google Scholar : PubMed/NCBI
17	Kitajima H, Takahashi H, Harada K, et al: Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers. Respirology. 11:217–220. 2006. View Article : Google Scholar : PubMed/NCBI
18	Sakoda Y, Kitasato Y, Kawano Y, et al: A case of alveolar hemorrhage caused by gefitinib. Nihon Kokyuki Gakkai Zasshi. 49:506–510. 2011.(In Japanese).
19	Goto Y, Hojo M, Takeda Y, et al: Gefitinib-induced interstitial lung disease - addition of intravenous cyclophosphamide to corticosteroids is a valuable treatment option: A case report. Med Oncol. 27:753–755. 2010. View Article : Google Scholar : PubMed/NCBI
20	Fukui T, Otani S, Hataishi R, et al: Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. Cancer Chemother Pharmacol. 65:803–806. 2010. View Article : Google Scholar : PubMed/NCBI
21	Su Y, Peng L and Wu YM: A case of gefitinib maintenance treatment of non-small cell lung cancer caused by interstitial pneumonia. Chongqing Medical Journal. 40:3102011.(In Chinese).
22	Peng W, Gao J and Miao LY: Death from pulmonary interstitial fibrosis and liver damage after taking gefitinib. Adverse Drug Reactions Journal. 11:429–430. 2009.(In Chinese).
23	Feng ZZ, Cao Y, Sun LM and Sun P: A cases of Gefitinib treatment of non-small cell lung cancer with finger bone metastasis caused interstitial pneumonia. Journal of Dalian Medical University. 30:588–589. 2008.(In Chinese).
24	Cui H, Huang Q and Chen Y: A case report of Gefitinib-induced interstitial pneumonia. J Clin Oncol. 12:235–237. 2007.
25	Liang H and Ynag H: A case of Gefitinib-induced interstitial pneumonia. Practical Journal of Medicine. 1:1622009.
26	Huang JH, Zhang Y and Zheng J: Interstitial pneumonia caused by gefitinib in one patient. Chinese Journal of New Drugs and Clinical Remedies. 26:878–879. 2007.(In Chinese).
27	Wang WL and Sun Y: One case of interstitial pneumonia caused by oral gefitinib and radiotherapy. Pharmaceutical and Clinical Research. 16:506–507. 2008.(In Chinese).
28	Zhou Y, Dai J, Zhu YZ and Chen FL: Gefitinib-induced interstitial pneumonia CT image analysis. China Modern Doctor. 12:61–62. 2010.(In Chinese).
29	Cao SF, Deng QN and Zhang DM: One case of epidermal growth factor receptor inhibitors-IRESA induced interstitial pneumonia. Journal of Guangdong College of Pharmacy. 20:304–305. 2004.(In Chinese).
30	Ciardiello F and Tortora G: EGFR antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008. View Article : Google Scholar : PubMed/NCBI
31	Hotta K, Kiura K, Takigawa N, et al: Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. J Thorac Oncol. 5:179–184. 2010. View Article : Google Scholar : PubMed/NCBI
32	Min JH, Lee HY, Lim H, et al: Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemother Pharmacol. 68:1099–1109. 2011. View Article : Google Scholar : PubMed/NCBI
33	Danson S, Blackhall F, Hulse P and Ranson M: Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf. 28:103–113. 2005. View Article : Google Scholar : PubMed/NCBI
34	Kudoh S, Kato H, Nishiwaki Y, et al: Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med. 177:1348–1357. 2008. View Article : Google Scholar : PubMed/NCBI
35	Armour A: Gefitinib in advanced non-small cell lung cancer: Clinical experience in patients of Asian origin. Asia Pac J Clin Oncol. 3:66–78. 2007. View Article : Google Scholar
36	American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 15:277–304. 2002.
37	Zhang Y, Yang H, Zhao M and He J: Successful treatment of gefitinib-induced acute interstitial pneumonitis with corticosteroid and non-invasive BIPAP-ventilation. J Thorac Dis. 4:316–319. 2012.PubMed/NCBI
38	Shih YN, Chiu CH, Tsai CM and Perng RP: Interstitial pneumonia during gefitinib treatment of non-small-cell lung cancer. J Chin Med Assoc. 68:183–186. 2005. View Article : Google Scholar : PubMed/NCBI